Top
image credit: Pexels

Biogen’s $1B Swiss plant scores regulatory nod as drugmaker awaits pivotal FDA decision on aducanumab

Despite a flurry of uncertainty surrounding Biogen’s Alzheimer’s hopeful aducanumab, the company has forged ahead with its launch preparations ahead of a pending FDA decision. Now, its Swiss manufacturing facility is a step closer to eventually churning out doses—should the drug score an approval.

Switzerland’s medicines surveillance authority, the Swiss Agency for Therapeutic Products (Swissmedic), issued Biogen’s Solothurn manufacturing facility a Good Manufacturing Practice (GMP) license, the company said.

Read More on FiercePharma